Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer, Introduces, "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid Derived Pharmaceutical Summit

Dr. Small-Howard will elucidate GB Sciences' Natural Products-Based Approach to Drug Discovery and is a panelist for the "Welcome Panel Session: Bringing Together Industry and Academia".

LAS VEGAS, Dec. 11, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced today that Dr. Andrea Small-Howard, Chief Science Officer and GB Sciences' Board Member, will present "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid-Derived Pharmaceuticals Summit ("iCDP Summit") in Boston, on December 11-12, 2018 at The Revere Hotel. The iCDP Summit is a central meeting place for leading pharma companies, research experts and clinical pioneers in the field of Cannabinoid Derived Pharmaceutical development ( http://international-cdp.com/about/about-event/ ).

"Together with our academic research partners, we are defining cannabinoid-containing complex mixtures ("CCCMâ„¢") that target specific diseases using a natural-products approach to drug discovery," explains Dr. Small-Howard. "Our lead compounds address Parkinson's disease by leveraging natural molecular synergies among the molecules in our proprietary CCCMâ„¢ to increase the net effectiveness of these complex API relative to single compound therapies."

In recognition of GB Sciences' commitment to university research partnerships, Dr. Small-Howard has also been asked to join the Welcome Panel: Bringing Together Industry and Academia. GB Sciences has assembled an exceptional international team of cannabinoid-based researchers from Chaminade University, Michigan State University, Louisiana State University AgCenter, University of Hawai'i, University of Athens in Greece, Universidad de Sevilla in Spain, Universidad de Cadiz in Spain, and the National Research Council of Canada. GB Sciences and their academic partners are working together to convert this powerful medicinal plant into more traditional medicines.

"GB Sciences is honored to be participating in this prestigious event with so many leading cannabinoid researchers, developers, and clinicians," said John Poss, CEO and Chairman of GB Sciences, Inc.

About GB Sciences, Inc.

GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.